An aggregate-forming coccus, isolated twice as the predominant microorganism in sputa from a cystic fibrosis patient on consecutive days, was shown to belong to the species Lautropia mirabilis on the bases of similarities of 16S rRNA gene sequences and phenotype. These isolates of L. mirabilis appear to be the first reported from a patient with cystic fibrosis and outside of Denmark.
An aggregate-forming gram-negative coccoid bacterium was isolated on two separate occasions in 1991 at the Royal North Shore Hospital, Sydney, Australia, as the predominant bacterium in sputum samples taken on consecutive days from a 35-year-old female patient with cystic fibrosis. The patient had been admitted to the hospital for intravenous antibiotic therapy for a chest infection in the upper lobe of both lungs. Her medical history showed that she was diagnosed with cystic fibrosis at 2 years of age when she presented with a failure to thrive. She was treated with the pancreatic enzyme supplement pancrelipase (Cotazym-S-Forte; Organon Australia Pty. Ltd.) and remained healthy until she stopped taking the supplement at 22 years of age. She subsequently developed steatorrhea and insulin-dependent diabetes mellitis. At 27 years of age she recommenced treatment with the pancreatic enzyme supplement and the steatorrhea settled.
Microscopic examination of a Gram-stained smear of her sputum taken on admission to the hospital showed numerous pus cells, gram-negative rods, and gram-positive cocci. A heavy growth of Haemophilus influenzae was cultured, along with a light growth of both Staphylococcus aureus and Pseudomonas aeruginosa. Burkholderia cepacia was not isolated. The patient was commenced on imipenem treatment (500 mg, 4 times daily) which was continued for 20 days. No maintenance antibiotics were given when she was finally discharged, and the patient did not present for a follow-up examination.
The aggregate-forming, gram-negative coccoid bacterium was first isolated on blood agar as the predominant microorganism from a sputum sample taken after 14 days of hospitalization and 2 weeks of antibiotic treatment. A Gram-stain of the sputum showed moderate numbers of pus cells and grampositive cocci only. However, the gram-negative coccus, along with a moderate background of pseudomonads, yeasts, and fungi, was cultured after 4 days of incubation. The same organism was isolated from a sputum sample taken the next day, and as the patient was not responding adequately to the imipenem treatment, further investigation of the first isolate was undertaken. Initial observation revealed superficial morphological similarity to the gram-negative agreggate-forming coccus Morococcus cerebrosus ACM 858 (3). However, the aggregate formations of the two bacteria are easily distinguishable (Fig. 1) . Thus, at the time of isolation the strain could not be assigned to any recognized species. The strain was accessioned into the Australian Collection of Microorganisms (Department of Microbiology, University of Queensland) as strain ACM 3763, and molecular characterization was undertaken to The extraction of genomic DNA and the amplification of the 16S rDNA was performed as described previously (1a) . The PCR products were purified by means of the Prep-A-Gene kit (Bio-Rad, Hercules, Calif.), used as described by the manufacturer. The Taq DyeDeoxy Terminator Cycle Sequencing Kit (Perkin-Elmer/Applied Biosystems, Foster City, Calif.) was used to directly sequence the PCR products, according to the protocol provided by the manufacturer, and the reaction mixtures were sequenced automatically on an Applied Biosystems model 373A DNA sequencer. The 16S rDNA sequence was aligned manually against representative bacterial 16S rDNA sequences contained in the Ribosomal Database Project (4). Positions where length and sequence variations made alignment uncertain were omitted from the analysis. Pairwise sequence similarities showed that the isolate belonged to the beta-subclass of the class Proteobacteria and was most closely related to a gram-negative aggregate-forming coccus isolated from the oral cavity of humans in Denmark and which was subsequently described as the type strain of Lautropia mirabilis in 1994 (2). Strain ACM 3763 was further characterized morphologically, and its biochemical profile was determined by a range of conventional tests (2, 3) to allow a comparison with the description of L. mirabilis. These results are shown in Table 1 , along with those previously determined for M. cerebrosus (3) and published for L. mirabilis (2) . Table 2 shows their antibiograms, as determined by the disk diffusion technique.
The phylogenetic and phenotypic data support the identification of the isolate from the cystic fibrosis patient as L. mirabilis. The analysis of 1,073 nucleotide positions of the 16S rDNA sequence of strain ACM 3763 covering the region from nucleotide 8 to 1073 (Escherichia coli numbering) showed 99.9% similarity to the sequence of the type strain of L. mirabilis, AB2188 (ϭNCTC 12852) (EMBL sequence accession number X73223). Comparison with a partial 16S rDNA sequence for M. cerebrosus (1) over 306 nucleotide positions showed only a distant phylogenetic relationship, with 80.2% sequence similarity. The phenotypic characteristics presented in Tables 1 and 2 are in close agreement with those of L. mirabilis except for hemolysis on horse blood agar and gas production from nitrate. The isolate was motile on isolation, but several attempts in two laboratories to repeat the demonstration of motility were unsuccessful. L. mirabilis was described (2) to include polymorphic gramnegative cocci from the oral cavity and upper respiratory tract which met Ørskov's (5) description of "Sarcina mirabilis," for which no strains are extant. Strains assigned to L. mirabilis were isolated from the oral cavity on Bordet-Gengou plates, from a frontal sinus drain of a patient recovering from a streptococcal sinusitis (2) , and from the gingival margins of healthy persons (6) . Gerner-Smidt et al. considered that although no evidence for pathogenicity exists, polysaccharide production from sucrose by this oral bacterium is compatible with a possible role in the formation of dental plaque (2) . There is also no evidence at this stage that L. mirabilis is clinically significant in cystic fibrosis. However, its occurrence in substantial numbers in the sputum of the patient in this study suggests that it may colonize the respiratory tract and lungs of persons with cystic fibrosis. It is hoped that this paper will alert clinical microbiologists to this possibility and that an increased awareness of this newly described organism will assist with the evaluation of its clinical significance.
Nucleotide sequence accession number. The rDNA sequence of L. mirabilis ACM 3763 determined in this study has been deposited in the EMBL Database, Cambridge, United Kingdom, under the accession number X97652. 
